CO2019013047A2 - Composiciones sólidas para administración oral - Google Patents

Composiciones sólidas para administración oral

Info

Publication number
CO2019013047A2
CO2019013047A2 CONC2019/0013047A CO2019013047A CO2019013047A2 CO 2019013047 A2 CO2019013047 A2 CO 2019013047A2 CO 2019013047 A CO2019013047 A CO 2019013047A CO 2019013047 A2 CO2019013047 A2 CO 2019013047A2
Authority
CO
Colombia
Prior art keywords
oral administration
solid compositions
glp
derivative
sglt2
Prior art date
Application number
CONC2019/0013047A
Other languages
English (en)
Inventor
Andreas Vegge
Susanne Schéele
Simon Bjerregaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59070439&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019013047(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2019013047A2 publication Critical patent/CO2019013047A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

RESUMEN La presente invención se refiere a composiciones sólidas para administración oral que comprenden (i) un derivado de GLP-1 y el inhibidor de SGLT2 dapagliflozina o (ii) un derivado de GLP-1 y una sal de NAC en combinación con un inhibidor de SGLT2.
CONC2019/0013047A 2017-06-09 2019-11-22 Composiciones sólidas para administración oral CO2019013047A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17175131 2017-06-09
PCT/EP2018/065266 WO2018224689A2 (en) 2017-06-09 2018-06-11 Solid compositions for oral administration

Publications (1)

Publication Number Publication Date
CO2019013047A2 true CO2019013047A2 (es) 2020-04-01

Family

ID=59070439

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013047A CO2019013047A2 (es) 2017-06-09 2019-11-22 Composiciones sólidas para administración oral

Country Status (28)

Country Link
US (2) US11167014B2 (es)
EP (1) EP3634468B1 (es)
JP (1) JP7239495B2 (es)
KR (1) KR20200015564A (es)
CN (1) CN110769846A (es)
AR (1) AR112015A1 (es)
AU (1) AU2018280875A1 (es)
BR (1) BR112019025769A2 (es)
CA (1) CA3064677A1 (es)
CL (1) CL2019003402A1 (es)
CO (1) CO2019013047A2 (es)
DK (1) DK3634468T3 (es)
ES (1) ES2938050T3 (es)
FI (1) FI3634468T3 (es)
HR (1) HRP20230075T1 (es)
HU (1) HUE060962T2 (es)
IL (1) IL270812B2 (es)
MA (1) MA49253A (es)
MX (1) MX2019013965A (es)
MY (1) MY197488A (es)
PE (1) PE20200606A1 (es)
PH (1) PH12019550249A1 (es)
PL (1) PL3634468T3 (es)
PT (1) PT3634468T (es)
RS (1) RS64045B1 (es)
SI (1) SI3634468T1 (es)
TW (1) TWI797133B (es)
WO (1) WO2018224689A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
KR102376009B1 (ko) * 2018-12-21 2022-03-18 (주)휴온스 엠파글리플로진 및 시타글립틴을 포함하는 약학적 조성물
CA3144611A1 (en) * 2019-08-07 2021-02-11 Betty Lomstein PEDERSEN Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US20220395559A1 (en) * 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023123063A1 (en) * 2021-12-29 2023-07-06 Guangzhou Dazhou Biomedicine Ltd. Oral delivery
EP4299052A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
WO2008144346A2 (en) 2007-05-18 2008-11-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for their preparation
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
JP2012528170A (ja) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
SI2498759T1 (sl) 2009-11-13 2018-12-31 Astrazeneca Ab Formulacije tablet s takojšnjim sproščanjem
DK2513140T3 (en) 2009-12-16 2016-01-18 Novo Nordisk As Double-acylated GLP-1 derivatives
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX355361B (es) * 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
EP4331667A2 (en) 2012-03-22 2024-03-06 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) * 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
JP6755175B2 (ja) 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
JP2018519313A (ja) * 2015-07-02 2018-07-19 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための治療剤製剤
WO2018096163A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
CA3144611A1 (en) * 2019-08-07 2021-02-11 Betty Lomstein PEDERSEN Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
CN110769846A (zh) 2020-02-07
TWI797133B (zh) 2023-04-01
US11167014B2 (en) 2021-11-09
HRP20230075T1 (hr) 2023-03-17
JP7239495B2 (ja) 2023-03-14
HUE060962T2 (hu) 2023-04-28
CA3064677A1 (en) 2018-12-13
DK3634468T3 (da) 2023-02-06
KR20200015564A (ko) 2020-02-12
AU2018280875A1 (en) 2019-12-12
IL270812B2 (en) 2024-01-01
MX2019013965A (es) 2020-01-23
EP3634468A2 (en) 2020-04-15
EP3634468B1 (en) 2022-12-14
PT3634468T (pt) 2023-03-28
BR112019025769A2 (pt) 2020-06-30
MA49253A (fr) 2020-04-15
JP2020522559A (ja) 2020-07-30
IL270812B1 (en) 2023-09-01
US20220016216A1 (en) 2022-01-20
US20200147179A1 (en) 2020-05-14
TW201904583A (zh) 2019-02-01
FI3634468T3 (fi) 2023-02-19
RU2019139082A3 (es) 2021-09-16
PL3634468T3 (pl) 2023-03-13
SI3634468T1 (sl) 2023-02-28
WO2018224689A3 (en) 2019-02-28
AR112015A1 (es) 2019-09-11
PH12019550249A1 (en) 2020-07-13
PE20200606A1 (es) 2020-03-10
RU2019139082A (ru) 2021-06-02
IL270812A (en) 2020-01-30
CL2019003402A1 (es) 2020-03-20
ES2938050T3 (es) 2023-04-04
WO2018224689A2 (en) 2018-12-13
RS64045B1 (sr) 2023-04-28
MY197488A (en) 2023-06-19

Similar Documents

Publication Publication Date Title
CO2019013047A2 (es) Composiciones sólidas para administración oral
CO2020014009A2 (es) Inhibidores de mcl-1
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
NI202100014A (es) Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto
GT201600070A (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
CO2019008087A2 (es) Método para modular la actividad de inflamasoma e inflamación en el pulmón
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
SV2018005778A (es) Derivados aromaticos de sulfonamida
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2020001394A1 (es) Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CL2020000586A1 (es) Moduladores de la expresión de enac.
CU20180110A7 (es) Una composición que comprende pic para el tratamiento del cáncer
CO2019005364A2 (es) Composiciones veterinarias y los usos de las mismas para prevenir y/o tratar infecciones parasitarias en mamíferos no humanos
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer